Understanding how immune modulation affects tumor initiation in pancreatic cancer
Dissecting mechanisms of tumor initiation via immunomodulation
This study is looking at how certain changes in a gene called Kras can lead to pancreatic cancer, with the goal of finding ways to detect it earlier and develop better treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clark Atlanta University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10784700 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the initiation of pancreatic cancer, particularly focusing on how mutations in the Kras gene influence the transformation of acinar cells into cancerous cells. By studying the acinar-to-ductal metaplasia (ADM) process, the research aims to uncover potential biomarkers for early detection and identify new drug targets for intervention. The approach involves analyzing the role of KrasG12D and KrasG12V mutations in the development of pancreatic ductal adenocarcinoma (PDAC) using transgenic mice and organoid models. Patients may benefit from advancements in early detection and treatment options stemming from this research.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for pancreatic cancer, particularly those with a family history or genetic predisposition.
Not a fit: Patients with advanced pancreatic cancer who are already diagnosed and have exhausted treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and more effective treatment options for pancreatic cancer patients.
How similar studies have performed: Other research has shown promise in targeting Kras mutations and understanding the ADM process, indicating potential for success in this area.
Where this research is happening
Atlanta, United States
- Clark Atlanta University — Atlanta, United States (Active)
Researchers
- Principal investigator: Liou, Geou-Yarh — Clark Atlanta University
- Study coordinator: Liou, Geou-Yarh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.